NASDAQ:OCX OncoCyte (OCX) Stock Forecast, Price & News $3.22 -0.02 (-0.62%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$3.10▼$3.2650-Day Range$3.19▼$4.1352-Week Range$3.10▼$16.94Volume25,217 shsAverage Volume19,503 shsMarket Capitalization$26.54 millionP/E RatioN/ADividend YieldN/APrice Target$7.31 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media OncoCyte MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside127.1% Upside$7.31 Price TargetShort InterestBearish2.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.49Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.09) to ($3.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector881st out of 961 stocksDiagnostic Substances Industry11th out of 12 stocks 3.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.31, OncoCyte has a forecasted upside of 127.1% from its current price of $3.22.Amount of Analyst CoverageOncoCyte has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.27% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in OncoCyte has recently increased by 3.50%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 1.4 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OncoCyte this week, compared to 1 article on an average week.MarketBeat Follows1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoCyte are expected to decrease in the coming year, from ($2.09) to ($3.57) per share.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoCyte (NASDAQ:OCX) StockOncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.comSeptember 18, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 21, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 18, 2023 | finance.yahoo.comOncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierSeptember 15, 2023 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.comSeptember 6, 2023 | finance.yahoo.comOncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageAugust 28, 2023 | finance.yahoo.comOncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS CoverageSeptember 21, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 24, 2023 | nasdaq.comBenchmark Maintains Oncocyte (OCX) Speculative Buy RecommendationAugust 15, 2023 | msn.comPiper Sandler Maintains Oncocyte (OCX) Neutral RecommendationAugust 11, 2023 | msn.comNeedham Maintains Oncocyte (OCX) Buy RecommendationAugust 10, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comOncocyte Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comOncocyte Regains Compliance With Nasdaq Listing RequirementsAugust 9, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Regains Compliance With Nasdaq Listing RequirementsAugust 8, 2023 | finance.yahoo.comOncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 ConferenceAugust 3, 2023 | finance.yahoo.comOncocyte To Announce Second Quarter 2023 Financial ResultsAugust 2, 2023 | msn.comOncocyte (OCX) Price Target Increased by 1900.00% to 7.14July 25, 2023 | finance.yahoo.comVitaGraft Kidney Expands Utility in Recurrent Primary Disease PatientsJuly 25, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Announces 1-For-20 Reverse Stock SplitJuly 24, 2023 | finance.yahoo.comOncocyte Announces 1-For-20 Reverse Stock SplitJuly 14, 2023 | finance.yahoo.comOCX - OncoCyte CorporationJune 27, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Begins Manufacturing Transplant Blood TestJune 27, 2023 | finance.yahoo.comOncocyte Begins Manufacturing Transplant Blood TestJune 1, 2023 | finance.yahoo.comOncocyte Corporation to Present at the LD Micro Invitational XIIIMay 11, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports First Quarter 2023 Financial ResultsSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Company Calendar Last Earnings8/10/2023Today9/21/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees75Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.31 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.25 Forecasted Upside/Downside+127.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,900,000.00 Net MarginsN/A Pretax Margin-1,472.21% Return on Equity-55.56% Return on Assets-25.03% Debt Debt-to-Equity RatioN/A Current Ratio2.74 Quick Ratio2.74 Sales & Book Value Annual Sales$1.10 million Price / Sales24.10 Cash Flow$0.87 per share Price / Cash Flow3.69 Book Value$5.78 per share Price / Book0.56Miscellaneous Outstanding Shares8,241,000Free Float8,081,000Market Cap$26.54 million OptionableOptionable Beta1.58 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 40)Pres, CEO & Director Comp: $373.2kMr. James Liu (Age 27)Sr. Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $192.48kMr. Yuh-Min Chiang Ph.D.Chief Technology OfficerDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMs. Sandra O'DonaldSr. VP of Bus. OperationsDr. Michael D. West Ph.D. (Age 70)Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. Peter HongSec.Ms. Sara RiordanDirector of Medical EducationMore ExecutivesKey CompetitorsTrinity BiotechNASDAQ:TRIBMyMD PharmaceuticalsNASDAQ:MYMDBiomericaNASDAQ:BMRAImmuCellNASDAQ:ICCCNavidea BiopharmaceuticalsNYSE:NAVBView All CompetitorsInsiders & InstitutionsPura Vida Investments LLCSold 541,141 shares on 8/14/2023Ownership: 165.352%AWM Investment Company Inc.Bought 7,412,613 shares on 8/11/2023Ownership: 172.156%Geode Capital Management LLCBought 236,099 shares on 8/11/2023Ownership: 14.910%BlackRock Inc.Sold 213,360 shares on 8/11/2023Ownership: 14.709%Renaissance Technologies LLCBought 78,500 shares on 8/11/2023Ownership: 1.676%View All Insider TransactionsView All Institutional Transactions OCX Stock - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price forecast for 2023? 4 brokerages have issued 1 year price targets for OncoCyte's stock. Their OCX share price forecasts range from $4.25 to $10.00. On average, they anticipate the company's stock price to reach $7.31 in the next year. This suggests a possible upside of 127.1% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2023? OncoCyte's stock was trading at $6.4180 on January 1st, 2023. Since then, OCX shares have decreased by 49.8% and is now trading at $3.22. View the best growth stocks for 2023 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) announced its earnings results on Thursday, August, 10th. The company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($2.60) by $1.53. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.60 million. When did OncoCyte's stock split? OncoCyte's stock reverse split before market open on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). What is OncoCyte's stock symbol? OncoCyte trades on the NASDAQ under the ticker symbol "OCX." Who are OncoCyte's major shareholders? OncoCyte's stock is owned by many different retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (172.16%), Pura Vida Investments LLC (165.35%), Geode Capital Management LLC (14.91%), BlackRock Inc. (14.71%), Renaissance Technologies LLC (1.68%) and LPL Financial LLC (1.55%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $3.22. How much money does OncoCyte make? OncoCyte (NASDAQ:OCX) has a market capitalization of $26.54 million and generates $1.10 million in revenue each year. How can I contact OncoCyte? OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389. This page (NASDAQ:OCX) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.